BNET Industries
Last Fiscal Year Sales:$17.5M
- Public
- US
Dow Jones Description
Tapestry Pharmaceuticals, Inc. is a company focused on developing proprietary therapies for the treatment of cancer. We are also actively engaged in evaluating new therapeutic agents and related technologies for in-licensing. Tapestry's technical expertise is our ability to identify, chemically alter and produce novel therapeutic compounds derived from natural product sources. Tapestry has developed a novel third generation taxane, TPI 287. In December 2004 we filed an IND application, and on January 21, 2005, we were cleared to proceed with clinical trials by the FDA.
Number of Employees 38
Contact Information
4840 Pearl E Cir Ste 300 W
Boulder, Colorado 80301-3320
(303) 516-8500
Peer Companies
NAICS Code Medicinal and Botanical Manufacturing: 325411
News & Analysis
Filter by
tapestry pharmaceuticals inc. - All News and Analysis
Webcast Alert: Tapestry Pharmaceuticals, Inc. Presentation at Informed Investors Biotechnology / Cancer On-line Investor Forum webcast on Thursday, October 6, 2005, 10:00 am ET
BOULDER, Colo. -- Tapestry Pharmaceuticals, Inc. (NASDAQ: TPPH) will present at the following forum: What: Tapestry Pharmaceuticals, Inc. (NasdaqNM: TPPH) will give a presentation at Informed Investors Biotechnology / Cancer On-line Investors Forum. When: October 6, 2005 @10:00 AM Eastern Time Where: http://www.informedinvestors.com/IIF/IIF_Forum.asp?ForumID=89498 How: Live over...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Leonard P. Shaykin | CEO |
| Donald Picker | President |
| Gordon Link | CFO & Senior Vice President |
| James D McChesney | Cso, Natural Products Chemistry |
| Martin M. Batt | Senior Vice President, Chief Operating Officer |
| Patricia A. Pilia | Executive Vice President |
| Brenda P. Fielding | Vice President, Regulatory Affairs |
| David L Emerson | Vice President, Cancer Biology |
| Gilles H Tapolsky | Vice President, Product Development |
| Kai P. Larson | Vice President, General Counsel |
| Larry Helson | Vice President, Bio Research |
| Matthew J. Majoros | Controller (Principal Accounting Officer) |
| George M. Gould | Attorney, of Counsel, Gibbons |
| Carter Stephen | Director |
| Edward L. Erickson | Director |
| Stephen K. Carter | Director |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Elliot M. Maza | Chair |
| Elliott M Maza | Chair |
| Arthur H. Hayes Jr. | Board of Directors |
| Daniel D. Von Hoff | Board of Directors |
| Eric K Rowinsky | Board of Directors |
| Marc J. Ostro | Board of Directors |
| Martin Cannon | Board of Directors |
| Richard N. Perle | Board of Directors |
| Robert E. Pollack | Board of Directors |
| S Gail Eckhardt | Board of Directors |
| Susan Band Horwitz | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Tapestry Pharmaceuticals Inc. | CEO | Current |
| Shaykin & Company | Managing Director | Current |
| Tapestry Pharmaceuticals Inc. | Manager | Current |
| Tapestry Pharmaceuticals Inc. | Chairman | Current |
| Jackson Laboratories | Board of Directors | Current |
| The Jackson Laboratory | Board of Directors | Current |
| American Center for Democracy | Board of Directors | Current |
| The Jackson Laboratory | Trustee | Current |
| Shaykin & Company | Founder | Former |
| Shaykin & Company | Managing Partner | Former |
| Citicorp Venture Capital, Ltd. | Board of Directors | Former |
| University of Chicago | M.A. | Former |
| University of Chicago Graduate School of Business | M.B.A. | Former |
| Citicorp Venture Capital, Ltd. | Member | Former |
| Citigroup Inc. | member | Former |
| Organization | Position | Status |
|---|---|---|
| Tapestry Pharmaceuticals Inc. | President | Current |
| Biovitas | Executive Vice President of Research and Development | Current |
| Xenomics, Inc. | Board of Directors | Current |
| Biovitas | Board of Directors | Current |
| Synergy Pharmaceuticals, Inc. | Chief Executive Officer | Former |
| LXR Biotechnology, Inc. | President | Former |
| Synergy Pharmaceuticals, Inc. | President | Former |
| LXR Biotechnology, Inc. | Chief Operating Officer | Former |
| Callisto Pharmaceuticals, Inc. | Executive Vice President of Research & Development | Current |
| Genta Incorporated | Senior Vice President of Research and Development | Former |
| Johnson Matthey, Inc. | Worldwide Vice President of R & D | Former |
| Fermavir Pharmaceuticals, Inc. | Co-Founder | Former |
| State University of New York at Albany | Ph.D. In Organic Chemistry | Former |
| State University of New York at Albany | Bachelor of Science In Chimica Al Brooklyn Polytechnic Institute. | Former |
| Organization | Position | Status |
|---|---|---|
| Tapestry Pharmaceuticals Inc. | CFO & Senior Vice President | Current |
| Tapestry Pharmaceuticals Inc. | Board of Directors | Current |
| Deloitte Touche Tohmatsu | Audit Manager | Former |
| Synergen, Inc. | Corporate Controller | Former |
| Rensselaer Polytechnic Institute | B.S. | Former |
| Metropolitan State College | B.A. In Accounting | Former |
| Organization | Position | Status |
|---|---|---|
| Tapestry Pharmaceuticals Inc. | Cso, Natural Products Chemistry | Current |
| The University of Mississippi | Professor and Chairman | Current |
| University of Mississippi | Professor | Former |
| University of Mississippi | Chairman | Former |
| The University of Mississippi | Director | Former |
Martin Batt has served as our Vice President, Chief Operating Officer since July 2004. Mr. Batt has also been Chief Information Officer since September 2002. Prior to joining us, from 1986 to August 2002, he was a Partner in the consulting firm of Grisanti, Galef & Goldress which specializes in operating and fixing distressed companies by providing leadership in senior executive positions. Mr. Batt has assumed various positions including CEO, President and Vice President in many industries including retailing, aerospace, communications, computer software, steel, computer hardware, carpet, apparel, and automotive parts manufacturing. Prior to that, Mr. Batt served in various Information Technology positions at U. S. Steel Corporation. Mr. Batt received a B.S. in Computer Sciences, Cum Laude, from Point Park College, Pittsburgh and has also taught Computer Science and Information Technology.
| Organization | Position | Status |
|---|---|---|
| Tapestry Pharmaceuticals Inc. | Senior Vice President, Chief Operating Officer | Current |
| Tapestry Pharmaceuticals Inc. | Board of Directors | Current |
| Point Park University | B.S. | Former |
| Organization | Position | Status |
|---|---|---|
| Tapestry Pharmaceuticals Inc. | Executive Vice President | Current |
| Regulus Pharmaceutical Consulting, Inc. | Consultant | Current |
| Tapestry Pharmaceuticals Inc. | Board of Directors | Current |
| Medical University of South Carolina | Assistant Professor | Former |
| Medical University of South Carolina | Ph.D. | Former |
| Medical University of South Carolina | M.S. | Former |
| Boston University | B.S. | Former |
| Organization | Position | Status |
|---|---|---|
| Tapestry Pharmaceuticals Inc. | Vice President, Regulatory Affairs | Current |
| Tapestry Pharmaceuticals Inc. | Director | Current |
| Tapestry Pharmaceuticals Inc. | Director, Regulatory Affairs | Former |
| Organization | Position | Status |
|---|---|---|
| Tapestry Pharmaceuticals Inc. | Vice President, Cancer Biology | Current |
| Gilead Sciences, Inc. | Senior Director | Former |
| OSI Pharmaceuticals, Inc. | Head of In Vivo Pharmacology | Former |
| Medical University of South Carolina | Ph.D. | Former |
| Organization | Position | Status |
|---|---|---|
| Tapestry Pharmaceuticals Inc. | Vice President, Product Development | Current |
| Flamel Technologies Incorporated | Former | |
| Rhone-Poulenc Rorer | Former | |
| University of Paris | Ph.D. In Chemistry | Former |
| Rice University | MBA | Former |
| Organization | Position | Status |
|---|---|---|
| Tapestry Pharmaceuticals Inc. | Vice President, General Counsel | Current |
| Tapestry Pharmaceuticals Inc. | Secretary | Current |
| Kirkland & Ellis LLP | Former | |
| Columbia University | J.D. | Former |
| Columbia University Law School | J.D. | Former |
| Brigham Young University | B.A. | Former |
| Brigham Young University | B.A. | Former |
| Organization | Position | Status |
|---|---|---|
| Tapestry Pharmaceuticals Inc. | Vice President, Bio Research | Current |
| Bio Research | Vice President | Current |
| New York Medical College | Head | Former |
| Tapestry Pharmaceuticals Inc. | Director | Former |
| Organization | Position | Status |
|---|---|---|
| Tapestry Pharmaceuticals Inc. | Controller (Principal Accounting Officer) | Current |
| Organization | Position | Status |
|---|---|---|
| Tapestry Pharmaceuticals Inc. | Attorney, of Counsel, Gibbons | Current |
| Tapestry Pharmaceuticals Inc. | Director | Current |
| Hoffmann-La Roche Inc. | Chief Patent Counsel | Former |
| Hoffmann-La Roche Inc. | Vice President, Licensing & Corporate Development | Former |
| Columbia University Law School | J.D. | Former |
| The Johns Hopkins University | B.A. In Organic Chemistry | Former |
| Organization | Position | Status |
|---|---|---|
| Intellect Neurosciences, Inc. | President | Current |
| Intellect Neurosciences, Inc. | Chief Financial Officer | Current |
| Tapestry Pharmaceuticals Inc. | Chair | Current |
| Intellect Neurosciences, Inc. | Board of Directors | Current |
| Emisphere Technologies, Inc. | Chief Financial Officer | Former |
| University of Pennsylvania Law School | J.D. | Former |
| Touro College | B.A. In Accounting | Former |
Elliot M. Maza, age 51, has served as a member of our Board of Directors since December 2004. Since May 2006, Mr. Maza has served as President and Chief Financial Officer of Intellect Neurosciences, Inc., a biopharmaceutical company specializing in the research and development of drugs to treat Alzheimer s disease and other major disorders of the central nervous system. From December 2003 to May 2006, Mr. Maza was Chief Financial Officer of Emisphere Technologies, Inc., a public biopharmaceutical company specializing in oral drug delivery. From March 1999 to December 2003, he was a partner at Ernst & Young LLP. Prior to that, Mr. Maza held various positions at Goldman Sachs & Co., J.P. Morgan Securities, Inc. and the law firm of Sullivan & Cromwell LLP. He is a certified public accountant. Mr. Maza received a B.A. in accounting from Touro College and a J.D. from the University of Pennsylvania Law School.
| Organization | Position | Status |
|---|---|---|
| Intellect Neurosciences, Inc. | Chief Financial Officer | Current |
| Tapestry Pharmaceuticals Inc. | Chair | Current |
| Intellect Neurosciences, Inc. | President | Former |
| Emisphere Technologies, Inc. | Chief Financial Officer | Former |
| University of Pennsylvania Law School | J.D. | Former |
| Touro College | B.A. In Accounting | Former |
| Organization | Position | Status |
|---|---|---|
| Quantrx Biomedical Corporation | Director of Quantrx | Current |
| Quantrx Biomedical Corporation | Board of Directors | Current |
| Tapestry Pharmaceuticals Inc. | Board of Directors | Current |
| Celgene Corporation | Board of Directors | Current |
| New York Medical College | Chief Executive Officer | Former |
| New York Medical College | President | Former |
| Penn State College of Medicine | President | Former |
| New York Medical College | Dean | Former |
| Penn State College of Medicine | Professor of Medicine | Former |
| Myriad Genetics, Inc. | Board of Directors | Former |
| Weill Medical College of Cornell University | M.D. | Former |
| University of Oxford | M.S. | Former |
| Santa Clara University | B.A. | Former |
Stephen K. Carter, M.D. has served on our Board of Directors since September 1998. Since 1997, Dr. Carter has been a consultant to the pharmaceutical industry. Dr. Carter was Senior Vice President of Research and Development at Boehringer Ingelheim Pharmaceuticals, Inc. from 1995 to 1997. Prior to joining Boehringer, Dr. Carter was Senior Vice President of Worldwide Clinical Research and Development at Bristol-Myers Squibb Company. From 1976 to 1982, Dr. Carter served as Director of the Northern California Cancer Program. Dr. Carter was also appointed to President Clinton's panel for AIDS drug development. Dr. Carter is a director of Allos Therapeutics, Alfacell Corporation, Emisphere Technologies, Inc. and Vion Pharmaceuticals Inc. and several privately held companies. Dr. Carter received an A.B. in History from Columbia College and an M.D. degree from New York Medical College. He completed a medical internship and residency at Lenox Hill Hospital.
| Organization | Position | Status |
|---|---|---|
| Emisphere Technologies, Inc. | Director | Current |
| Vion Pharmaceuticals, Inc. | Director | Current |
| Cytogen Corporation | Director | Current |
| Alfacell Corp | Director | Current |
| Allos Therapeutics, Inc. | Director | Current |
| Callisto Pharmaceuticals, Inc. | Director | Current |
| Tapestry Pharmaceuticals Inc. | Director | Current |
| Celator Pharmaceuticals | Director | Current |
| Bristol-Myers Squibb Company | Senior Vice President of Worldwide Clinical Research and Development | Former |
| New York Medical College | M.D. Degree | Former |
| Columbia College | A.B. In History | Former |
| Organization | Position | Status |
|---|---|---|
| Tgen | Executive Vice President, Physician-In-Chief | Current |
| Systems Medicine Inc. | Founder and Cmo | Current |
| US Oncology, Inc. | Chief Scientific Officer | Current |
| Grayhawk Venture Partners | Executive Vice President of Tgen, Director of Tgen's Translational Drug Development Division | Current |
| Cylene Pharmaceuticals, Inc. | Co-Founder and Vice President, Medical Affairs | Current |
| Molecular Profiling, Inc. | Executive Director, Tissue Banking and Analysis Center Inc. | Current |
| ILEX Oncology, Inc. | Founder | Current |
| Ilex Ltd. | Founder | Current |
| The Side-Out Foundation | Clinical Oncologist and Oncology Drug Developer | Current |
| Adventrx Pharmaceuticals Inc | Professor of Medicine, Pathology, Molecular | Current |
| Synta Pharmaceuticals Corp. | Professor of Medicine, Pathology, Molecular and Cellular Biology | Current |
| Innovive Pharmaceuticals, Inc. | Dr. Von Hoff Is Senior Investigator | Current |
| Pathology Inc. | Professor | Current |
| The University of Arizona | Professor of Medicine, Molecular and Cellular Biology, and Pathology | Current |
| Pcrt | Professor of Medicine, Pathology, Molecular | Current |
| Boston Millennia Partners Co | Strategic Advisor | Current |
| Medelis, Inc. | Senior Investigator | Current |
| Adherex Technologies, Inc. | Professor of Pathology, Molecular | Current |
| Spectrum Pharmaceuticals Inc. | Current | |
| Nereus Pharmaceuticals, Inc. | Current | |
| Antigenics Inc. | Current | |
| Medical Consultant Services | Current | |
| Tracon Pharmaceuticals, Inc. | Chair | Current |
| Jennerex Biotherapeutics, Inc. | Chair | Current |
| Mersana Therapeutics, Inc | Board of Directors | Current |
| Genta Incorporated | Board of Directors | Current |
| Pharmacyclics, Inc. | Board of Directors | Current |
| Molecular Profiling, Inc. | Board of Directors | Current |
| Innovive Pharmaceuticals, Inc. | Board of Directors | Current |
| Clavis Pharma | Board of Directors | Current |
| Glyconix Corp | Board of Directors | Current |
| Vidacare Corporation | Board of Directors | Current |
| Astex Therapeutics Limited | Board of Directors | Current |
| ArQule, Inc. | Board of Directors | Current |
| Cylene Pharmaceuticals, Inc. | Board of Directors | Current |
| Imquest Pharmaceuticals, Inc. | Board of Directors | Current |
| Adherex Technologies, Inc. | Board of Directors | Current |
| Ilex Ltd. | Board Member | Current |
| Synta Pharmaceuticals Corp. | Board of Directors | Current |
| Erimos Pharmaceuticals Inc | Board of Directors | Current |
| Boston Millennia Partners Co | Board of Directors | Current |
| The University of Arizona | Director | Current |
| Genetics Squared | Board of Directors | Current |
| The Lustgarten Foundation | Board of Directors | Current |
| Unibioscreen | Board of Directors | Current |
| Tapestry Pharmaceuticals Inc. | Board of Directors | Current |
| American College of Physicians | Fellow | Current |
| Aacr | President | Former |
| US Oncology, Inc. | Co-Director | Former |
| Memorial Sloan-Kettering Cancer Center Inc. | Associate Member | Former |
| Tgen | Head of Pancreatic Cancer Research | Former |
| University of California | internship | Former |
| University of Texas Health Science Center at San Antonio | Professor | Former |
| San Francisco | internship | Former |
| The University of Texas at Austin | Clinical Professor | Former |
| Arizona Cancer Center | Prof of Medicine | Former |
| Cancer Research | Associate Editor | Former |
| One, Inc. | co-editor | Former |
| The University of Texas | Former | |
| Institute for Drug Development | Director | Former |
| The Annals | Board of Directors | Former |
| American Journal of Medicine | Board of Directors | Former |
| Aacr | Board of Directors | Former |
| Asco | Board Member | Former |
| ILEX Oncology, Inc. | Board Member | Former |
| American Society of Clinical Oncology | Board Member | Former |
| Columbia University | M.D. | Former |
| Columbia University College of Physicians and Surgeons | MD | Former |
| Carroll College | Former |
| Organization | Position | Status |
|---|---|---|
| Tapestry Pharmaceuticals Inc. | Director | Current |
Dr. Rowinsky is the Director of the Institute for Drug Development, Cancer Therapy and Research Center and Chief Medical Officer of Imclone, Inc. He serves as the Editor-in-Chief of Investigational New Drugs and as an Associate Editor for various publications, including Cancer Research. Dr. Rowinsky also serves on the NCI Board of Scientific Counselors. He is actively involved in preclinical and clinical research in anticancer drug development and has played pivotal roles in the regulatory approval of a large number of contemporary anticancer therapeutics such as Taxotere . Dr. Rowinsky received his M.D. from the Vanderbilt School of Medicine.
| Organization | Position | Status |
|---|---|---|
| Tapestry Pharmaceuticals Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Tapestry Pharmaceuticals Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Tapestry Pharmaceuticals Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Tapestry Pharmaceuticals Inc. | Board of Directors | Current |
Dr. Pollack grew up in Brooklyn, attended public schools, and graduated from Columbia College with a major in physics in 1961. He holds a Ph.D. in biology from Brandeis University. He is Professor of Biological Sciences, Lecturer in Psychiatry at the Center for Psychoanalytic Training and Research, and Director of the Center for the Study of Science and Religion, at Columbia University since 1978, and was Dean of Columbia College from 1982 to 1989. He received the Alexander Hamilton Medal from Columbia University, and has held a Guggenheim Fellowship. Dr. Pollack is the author of more than a hundred research papers on the oncogenic phenotype of mammalian cells in culture, and has edited many books and reviews on aspects of molecular biology. Since 1994 Dr. Pollack has concentrated his efforts on questions that lie at the margin of science and religion. His latest work, "The Faith of Biology and the Biology of Faith: order, meaning and free will in modern science," was published in 2000, as the inaugural volume of a Columbia University Press series of books on Science and Religion. He is currently working on a book on childhood depression. Since 1998 Dr. Pollack has been the President of the Hillel of Columbia University and Barnard College, located in the new Robert K. Kraft Family Center for Jewish Student Life.
| Organization | Position | Status |
|---|---|---|
| Ctns Co | Professor of Biological Sciences and Director, Center | Current |
| Mind & Reality Symposium | Director of the Cssr | Current |
| The Program Inc | Senior Consultant | Current |
| Center for The Study | Adjunct Professor of Environmental, Ecological and Evolutionary Biology | Current |
| Union Theological Seminary | Professor of Biological Sciences | Current |
| Fathom Knowledge Network Privacy | Current | |
| Signs, Ltd. | Current | |
| Ctns Co | Board of Directors | Current |
| Center for The Study | Director | Current |
| Tapestry Pharmaceuticals Inc. | Board of Directors | Current |
| Aaas.Com | Fellow | Current |
| Columbia College | Dean | Former |
| NYU Medical Center | Assistant Professor | Former |
| Weizmann Institute of Science | Research Scientist | Former |
| Tapestry Pharmaceuticals Inc. | Chair | Former |
| Brandeis University | Ph.D. in biology | Former |
| Columbia University | B.A. In Physics | Former |
Dr. Eckhardt is a Professor of Medicine and the Director of the Developmental Therapeutics and GI Malignancies Programs at the University of Colorado Health Science Center in Denver. She is a member of the ASCO Board of Directors and ASCO Publications Committee. She previously worked as an Associate Director of Clinical Research, Cancer Therapy and Research Center at the Institute for Drug Development in San Antonio, Texas. Dr. Eckhardt received her M.D. from the University of Texas Medical Branch in Galveston.
| Organization | Position | Status |
|---|---|---|
| Tapestry Pharmaceuticals Inc. | Board of Directors | Current |
| Institute for Drug Development | Associate Director of Clinical Research | Former |
Stephen K. Carter, M.D., a Director of the Company since 2003, is the former Senior Vice President, Clinical and Regulatory Affairs, of Sugen, Inc. (ownership of Sugen has since passed to Pfizer, Inc. as part of its acquisition of Pharmacia in April 2003). Dr. Carter previously was the Senior Vice President, Research and Development of Boehringer Ingelheim Pharmaceuticals, Inc., now independently owned. Prior to this, he served 13 years at Bristol-Myers Squibb Co., including, as its Senior Vice President, Worldwide Clinical Research and Development. Dr. Carter is a former Deputy Director at the National Cancer Institute (NCI)'s Division of Cancer Treatment and is a member of the American Society of Clinical Oncology. He received his Medical Doctorate from New York Medical College. He is currently a member of the boards of directors of Alfacell Corporation, Achillion Pharmaceuticals, Inc., Cytogen Corporation, Sopherion Therapeutics, Inc., and Vion Pharmaceuticals, Inc.
| Organization | Position | Status |
|---|---|---|
| Emisphere Technologies, Inc. | Director of the Company | Current |
| Threshold Pharmaceuticals, Inc. | Current | |
| Callisto Ltd. | Current | |
| Sunesis Pharmaceuticals, Inc. | Current | |
| Anisfield-Wolf Book Awards | Current | |
| Onconase | Board of Directors | Current |
| Allos Therapeutics, Inc. | Director | Current |
| Society of Surgical Oncology | Board of Directors | Current |
| Amphora Discovery Corporation | Board of Directors | Current |
| Cytogen Corporation | Director | Current |
| American Association for Cancer Research, Inc. | Board of Directors | Current |
| The American Law Institute | Board of Directors | Current |
| Emisphere Technologies, Inc. | Board of Directors | Current |
| Aspen Institute | Board of Directors | Current |
| Tapestry Pharmaceuticals Inc. | Director | Current |
| Alfacell Corp | Director | Current |
| American Society of Clinical Oncology | Board of Directors | Current |
| The Celator | Board of Directors | Current |
| Celator Pharmaceuticals | Director | Current |
| American Association for Cancer Research, Inc. | Member | Current |
| The American Law Institute | Member | Current |
| Aspen Institute | Trustee | Current |
| Bristol-Myers Squibb Company | Senior Vice President, Worldwide Clinical Research and Development | Former |
| United States Court of Appeals for the District of Columbia Circuit | Clerk | Former |
| NCI, Inc. | Former | |
| New York Medical College | M.D. | Former |
| Vion Pharmaceuticals, Inc. | Board of Directors | Current |
| Columbia College | A.B. | Former |
| Stanford University | Bachelor's Degree | Former |
| Columbia University | B.A. | Former |
| Yale University | Degree | Former |
| New York Medical College | Degree | Former |
| Stanford University | member | Former |
Dr. Susan Band Horwitz is a Distinguished University Professor and the Rose C. Falkenstein Professor of Cancer Research. She is Co-Chair of the Department of Molecular Pharmacology at the Albert Einstein College of Medicine and Associate Director for Therapeutics at the Albert Einstein Cancer Center. Dr. Horwitz has had a continuing interest in natural products as a source of new drugs for the treatment of cancer. Her laboratory has made Taxol, a drug isolated from the yew plant, Taxus brevifolia, a major focus of its work. Dr. Horwitz and her collaborators demonstrated that the effects of Taxol were due to a novel interaction between the drug and microtubules, the latter being essential for the pairing and segregation of chromosomes during cell division.
| Organization | Position | Status |
|---|---|---|
| Albert Einstein College of Medicine | Co-Chair | Current |
| Tapestry Pharmaceuticals Inc. | Board of Directors | Current |
| Brandeis University | Ph.D. In Biochemistry | Former |
| Bryn Mawr College | B.A | Former |
Executive News
-
Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine
-
Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today...
-
Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine
-
Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine
Industry Transcripts by Seeking Alpha
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
-
Arena Pharmaceuticals Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ARNA
-
Javelin Pharmaceuticals, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about JAV
-
Alexza Pharmaceuticals, Inc., Q3 2009 Earnings Call Transcript
on Nov 09, 2009about ALXA
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Best Selling Drugs Will Soon be Biologics, But Not Owned by Biotechs 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes



